Orexigen™ Announces Positive Clinical Results of Its Proprietary Naltrexone Sustained Release Formulation for Use in Contrave™
On September 25, 2007, Orexigen™ Therapeutics, Inc announced positive results for their two Phase I trials of a new sustained release formulation of naltrexone, which is the main ingredient in Orexigen's™ new weight loss drug Contrave™, which is currently in Phase III trials.
The first trial compared the immediate release naltrexone with the newer sustained release naltrexone. Results showed that the sustained release version reduced peak blood concentration by about 25% and fewer users had more than one adverse event.
The second trial included a combination of bupropion SR with either naltrexone SR or naltrexone IR. This is the drug combination used in Orexigen's™ diet drug Contrave™. The results showed that there were fewer adverse effects from the sustained release version, as opposed to the immediate release type.
Technorati Tags: Contrave™ naltrexone Diet Pills Weight Loss Pillsbupropion
The first trial compared the immediate release naltrexone with the newer sustained release naltrexone. Results showed that the sustained release version reduced peak blood concentration by about 25% and fewer users had more than one adverse event.
The second trial included a combination of bupropion SR with either naltrexone SR or naltrexone IR. This is the drug combination used in Orexigen's™ diet drug Contrave™. The results showed that there were fewer adverse effects from the sustained release version, as opposed to the immediate release type.
Technorati Tags: Contrave™ naltrexone Diet Pills Weight Loss Pillsbupropion
Labels: bupropion, contrave, diet pill, weight loss, weight loss pills
posted by Ken MacKenzie @ 3:01 PM
0 Comments:
Post a Comment
<< Home